NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-143-2017-0-JP-05 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range JP National Stage 2020-510560 Issued
NIAID E-106-2016-0-US-04 PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE US National Stage 16/079,972 11191821 Issued PDF
NCI E-143-2017-0-NL-10 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range NL EP 18765321.7 Issued
NCI E-143-2017-0-SE-11 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range SE EP 18765321.7 Issued
NCI E-143-2017-0-EP-04 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range EP National Stage 18765321.7 Issued
NCI E-143-2017-0-CH-07 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range CH EP 18765321.7 Issued
NCI E-143-2017-0-GB-09 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range GB EP 18765321.7 Issued
NCI E-143-2017-0-DE-08 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range DE EP 18765321.7 Issued
NHGRI E-217-2007-0-JP-16 N-ACETYL MANNOSAMINE AS A THERAPEUTIC AGENT JP DIV 2018-156853 Issued
NCI E-143-2017-0-PCT-02 Conformational Restriction Of Cyanine Fluorophores In Far-red And Near-lR Range PCT PCT PCT/US2018/047876 Expired
NIAID E-236-2018-0-PCT-02 Monoclonal Antibody Against Spike Protein Of Middle East Respiratory Syndrome Coronavirus And Uses Thereof PCT PCT PCT/KR2018/009754 Expired
NCI E-055-2011-0-US-05 BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USE US DIV 16/107,559 11357839 Issued PDF
NCI E-015-2011-0-US-12 NUCLEAR RECEPTOR MODULATORS AND THEIR USE FOR THE TREATMENT AND PREVENTION OF CANCER US DIV 16/107,532 10737995 Issued PDF
NCI E-291-2012-0-US-17 M971 CHIMERIC ANTIGEN RECEPTORS US DIV 16/107,271 10703816 Issued PDF
NEI E-165-2017-0-PCT-02 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES PCT PCT PCT/US2018/047064 Expired
NCI E-767-2013-0-US-08 Certain Improved Human Bispecific EGFRvIII Antibody Engaging Molecules US CON 16/105,425 Abandoned
NEI E-165-2017-0-CN-03 COMPOSITIONS AND METHODS TO PROTECT MAMMALIAN TISSUE AGAINST COLD AND OTHER METABOLIC STRESSES CN National Stage 201880068155.5 Pending
NIBIB E-006-2016-0-DE-08 Systems and Methods for Instant Total Internal Reflection Fluorescence/Structured Illumination Microscopy DE EP 17844356.0 Issued
NIBIB E-006-2016-0-FR-09 Systems and Methods for Instant Total Internal Reflection Fluorescence/Structured Illumination Microscopy FR EP 17844356.0 Issued
NIBIB E-006-2016-0-CH-07 Systems and Methods for Instant Total Internal Reflection Fluorescence/Structured Illumination Microscopy CH EP 17844356.0 Issued
NIBIB E-006-2016-0-GB-10 Systems and Methods for Instant Total Internal Reflection Fluorescence/Structured Illumination Microscopy GB EP 17844356.0 Issued
NIBIB E-006-2016-0-EP-03 Systems and Methods for Instant Total Internal Reflection Fluorescence/Structured Illumination Microscopy EP National Stage 17844356.0 Issued
NHLBI E-175-2017-0-US-03 Hybrid CT System With Additional Detectors In Close Proximity To The Body US National Stage 16/639,469 1124-12-07 Issued PDF
NCI E-148-2011-0-EP-17 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer EP DIV 18188913.0 Issued
NCI E-148-2011-0-NL-49 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer NL EP 18188913.0 Issued
NCI E-148-2011-0-CH-42 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer CH EP 18188913.0 Issued
NCI E-148-2011-0-GB-46 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer GB EP 18188913.0 Issued
NCI E-148-2011-0-PT-50 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer PT EP 18188913.0 Issued
NCI E-148-2011-0-ES-44 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer ES EP 18188913.0 Issued
NCI E-148-2011-0-AT-40 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer AT EP 18188913.0 Issued
NCI E-148-2011-0-BE-41 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer BE EP 18188913.0 Issued
NCI E-148-2011-0-DE-43 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer DE EP 18188913.0 Issued
NCI E-148-2011-0-FR-45 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer FR EP 18188913.0 Issued
NCI E-148-2011-0-IE-47 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer IE EP 18188913.0 Issued
NCI E-148-2011-0-IT-48 Anti-Epidermal Growth Factor Receptor Variant III Chimeric Antigen Receptors And Use Of Same For The Treatment Of Cancer IT EP 18188913.0 Issued
NHLBI E-175-2017-0-PCT-02 Hybrid CT System With Additional Detectors In Close Proximity To The Body PCT PCT PCT/US2018/046666 Expired
NCI E-136-2018-1-US-11 Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab US National Stage 16/077,720 Pending
NLM E-110-2016-2-JP-05 Novel CRISPR Enzymes And Systems JP National Stage 2018-561179 Pending
NLM E-111-2016-7-JP-05 Novel CRISPR Enzymes And Systems JP National Stage 2018-561180 Abandoned
NLM E-111-2016-7-CN-06 Novel CRISPR Enzymes And Systems CN National Stage CN PCT/US2016/038258 Pending
NLM E-110-2016-2-CN-06 Novel CRISPR Enzymes And Systems CN National Stage CN PCT/US2016/038238 Pending
NLM E-111-2016-7-EP-04 Novel CRISPR Enzymes And Systems EP National Stage 16742455.5 Issued
NLM E-111-2016-7-DK-01 Novel CRISPR Enzymes And Systems DK EP 16742455.5 Issued
NLM E-111-2016-7-NL-01 Novel CRISPR Enzymes And Systems NL EP 16742455.5 Issued
NLM E-111-2016-7-LU-01 Novel CRISPR Enzymes And Systems LU EP 16742455.5 Issued
NLM E-111-2016-7-LI-01 Novel CRISPR Enzymes And Systems LI EP 16742455.5 Issued
NLM E-111-2016-7-IS-01 Novel CRISPR Enzymes And Systems IS EP 16742455.5 Issued
NLM E-111-2016-7-IE-01 Novel CRISPR Enzymes And Systems IE EP 16742455.5 Issued
NLM E-111-2016-7-GB-01 Novel CRISPR Enzymes And Systems GB EP 16742455.5 Issued
NLM E-111-2016-7-CH-01 Novel CRISPR Enzymes And Systems CH EP 16742455.5 Issued